The results were the company's first since its March capital markets day, when it said it would grow top-line production and increase shareholder returns over the next five years. Cigna Group swung to ...

A decision is expected in the fourth quarter of 2025.

Kyle Richards’ daughter Sophia Umansky detailed the unexpected side effects that surfaced four months after she started ...

The Bagsvaerd, Denmark, company said that if the application is approved, Wegovy would become the first oral formulation of a ...

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

The company’s health services division Evernorth is doubling down on a reliable growth area: assuaging payer concerns around ...

Ozempic’s popularity for weight loss is growing, and according to a 2024 survey from KFF, about two in five adults in the US ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Cigna (NYSE:CI) on Friday announced plans to launch a new specialized GLP-1 pharmacy called ENGUIDE from next month, as the ...

Cigna, which comprises the Evernorth Health Services division and the Cigna Healthcare insurance business, reported a 19% ...

Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease ...